Trial-by-gene · BRAF V600

Active clinical trials enrolling BRAF V600-mutant melanoma

Decision-support aid only — eligibility decisions must be confirmed against the actual trial protocol and the patient's medical record. Trial counts and statuses change daily; this page is for orientation, not adjudication.

BRAF V600 melanoma trials span (1) adjuvant therapy duration and combination optimization, (2) ICI-resistance trials adding BRAF/MEK or repurposing combinations, (3) BRAF + MEK + ICI triplet sequencing, and (4) CNS-active regimens for brain metastases.

See the BRAF melanoma cheat sheet.

Browse the live listing

Search ClinicalTrials.gov for actively recruiting melanoma trials with BRAF V600-directed interventions.

Open ClinicalTrials.gov listing

Source: ClinicalTrials.gov, US National Library of Medicine. Trial-listing data is in the public domain. Use of ClinicalTrials.gov data must comply with the NLM terms of use.

Representative trial phases and designs

Phase III, adjuvant

Dabrafenib + trametinib adjuvant in resected stage III BRAF V600-mutant melanoma.

Phase II, ICI-resistant

Encorafenib + binimetinib in melanoma progressing on immune checkpoint inhibitor.

Phase I/II, triplet

BRAF + MEK + anti-PD-1 triplets, sequencing optimization.

Frequently asked questions

Sequencing: BRAF+MEK or ICI first in V600?
Active question across multiple trials. DREAMseq and SECOMBIT helped clarify; ICI-first generally favored for fit patients with V600-mutant disease, with BRAF+MEK reserved for ICI failure or symptomatic-burden cases.

Related